Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Dr Reddy’s Laboratories ( (RDY) ) has issued an update.
Dr. Reddy’s Laboratories has disclosed that its wholly owned subsidiary, Dr. Reddy’s Laboratories SA, is affected by a major clinical setback involving its partner Immutep SAS. On March 13, 2026, Immutep said an Independent Data Monitoring Committee recommended discontinuing the TACTI-004 Phase III trial of Eftilagimod alfa in first-line non-small cell lung cancer after a planned interim futility analysis.
Following the committee’s recommendation, patient enrolment in TACTI-004 will stop and Immutep will conduct an orderly wind-down of the study, including follow-up and site closure in line with regulatory and ethical requirements. Dr. Reddy’s noted it has so far only made the upfront payment under its exclusive licensing and collaboration deal and is in ongoing discussions with Immutep on the future of the Eftilagimod alfa program, limiting its immediate financial exposure but raising uncertainty over a previously anticipated oncology asset.
The most recent analyst rating on (RDY) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Dr Reddy’s Laboratories stock, see the RDY Stock Forecast page.
Spark’s Take on RDY Stock
According to Spark, TipRanks’ AI Analyst, RDY is a Outperform.
The score is driven primarily by strong fundamentals (profitability, growth, and low leverage), tempered by weaker cash-flow conversion. Earnings-call takeaways are moderately positive due to pipeline progress and strong liquidity, but near-term margins and regulatory delays add risk. Technicals are neutral-to-soft and valuation is reasonable with a low dividend yield.
To see Spark’s full report on RDY stock, click here.
More about Dr Reddy’s Laboratories
Dr. Reddy’s Laboratories is an India-based global pharmaceutical company focused on the development, manufacture and commercialization of generic medicines and specialty therapies. Through its subsidiaries, including Dr. Reddy’s Laboratories SA, the company pursues strategic collaborations to expand its portfolio of innovative treatments across key international markets outside North America, Europe, Japan and Greater China.
Average Trading Volume: 1,730,449
Technical Sentiment Signal: Strong Buy
Current Market Cap: $11.92B
See more insights into RDY stock on TipRanks’ Stock Analysis page.